Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
Pear Therapeutics and PreferredOne Announce Broad Based Patient Access and Reimbursement for reSET® and reSET-O® for People with Substance Use Disorder and Opioid Use Disorder
Read Article
News
2020
2019
Archive
September 21, 2020
Pear Therapeutics and PreferredOne Announce Broad Based Patient Access and Reimbursement for reSET® and reSET-O® for People with Substance Use Disorder and Opioid Use Disorder
September 21, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 14, 2020
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCS at IDWeek 2020
September 14, 2020
Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase I/Ib Clinical Trial of EP547, a MRGPR-Targeted Therapy to Treat Cholestatic and Uremic Pruritus
September 9, 2020
Cleave Therapeutics Announces Preclinical Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)
September 3, 2020
Rallybio Appoints Helen M. Boudreau to Board of Directors
September 3, 2020
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
September 1, 2020
Pear Therapeutics Announces Data From Two Studies Evaluating Somryst™ for Chronic Insomnia Presented at Virtual Sleep 2020
September 1, 2020
Vor Biopharma and Metagenomi to Collaborate on Engineered Hematopoietic Stem-Cell Therapies
August 27, 2020
RareCyte Announces First Commercially Available ARv7/Synaptophysin CTC Assay for Blood-Based Characterization of Treatment Resistant Prostate Cancer
1
2
3
…
10
Next Page »
